Chenghe Acquisition III Co. filed its Form 10-Q for the quarter ended September 30, 2026, with the SEC on November 12, 2026, reporting quarterly net income of $975,037 and total assets of $131,521,148.
Imunon, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the fiscal quarter ended September 30, 2026, disclosing condensed consolidated financial statements and management discussion for the period.
Vivani Medical, Inc. filed a Form 8-K on November 12, 2026, reporting top-line results from its SLIM-1 Phase 1 clinical trial of NPM-139, a semaglutide implant, alongside its third quarter 2026 financial results.
Patriot National Bancorp, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 12, 2026, reporting a return to quarterly net income after a year-to-date loss.
Kyverna Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the three and nine months ended September 30, 2026, disclosing a net loss of $41.9 million for the quarter and total stockholders' equity of $133.2 million.
Creatd, Inc. filed a Form 10-Q with the SEC on November 12, 2026, covering the quarterly period ended September 30, 2026, disclosing a net loss of $2,855,134 from continuing operations for the three months ended September 30, 2026.
Lucid Diagnostics Inc. filed its Form 10-Q with the SEC on November 12, 2026, covering the quarterly period ended September 30, 2026, disclosing a net loss of $6.7 million for the third quarter and $32.3 million for the nine months ended September 30, 2026.
SeaStar Medical Holding Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 12, 2026, reporting financial results for the three and nine months ended on that date.
Theriva Biologics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the three and nine months ended September 30, 2026, disclosing a continued operating loss alongside a significant reduction in operating expenses compared to the prior-year period.
CorMedix Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the Securities and Exchange Commission on November 12, 2026, reporting a net loss of $14.7 million for the third quarter and net income of $49.9 million for the nine-month …